

# Smith & Nephew

**Healthcare equipment & services**
**10 November 2017**

## No distractions from the search for growth

Smith & Nephew's Q317 results featured 9% revenue growth in emerging markets that continued the trend of previous quarters. A further efficiency review looks likely to focus on reducing complexity in manufacturing and warehousing, improving the G&A ratio and continued salesforce efficiency. A narrowing of the FY revenue and profit growth expectations towards the lower end of the previously guided range may have disappointed some, but this close to the year-end there should be confidence that the revised FY ranges will remain intact. Management does not comment on M&A speculation, but with the recently announced retirement of its CEO, S&N's continued strength in the attractive emerging markets and rumoured activist interest look likely to stoke further media speculation.

## Emerging markets remain the Q3 highlight

Reported revenues of \$1.15bn were up 3% compared to Q316 and while established market growth was just 1%, the US led with 2% revenue growth. Once again the emerging market business was the star with 9% revenue growth; just below the double-digits of H1. On a franchise basis, there were a number of moving parts with Reconstruction returning to 4% growth led by above-market 6% growth in knee implants. At the more exciting end of the business, Advanced Wound Management revenues grew by 2% and management remains excited about the expanding indications for the NAVIO Robotic Surgical System. Other drivers in the quarter included a \$5-6m hit due to hurricane season.

## FY 2017 Guidance ranges narrowed

Any disappointment on the guidance towards the bottom end of the previously announced FY 3-4%, and 20-70bp revenue and profit ranges, respectively was tempered by a press backdrop of S&N as an M&A target. Any company announcing the retirement of its CEO, with rumoured activist interest and with emerging market growth to which competitors would aspire, is likely to be subject to such speculation. In any event, continued growth in emerging markets and further business simplification plans are likely to appeal to both investors and potential acquirers.

## Valuation: Between its bigger US peers

S&N currently trades at c 20x consensus FY17e P/E; between its US peers Stryker (c 24x) and Zimmer (c 13x). Stryker's premium to S&N may be due to its improved portfolio balance and robotics focus. Its US competitors have respective 11% and 15% Asia Pacific sales but neither has S&N's Emerging Market growth prospects.

### Consensus estimates

Year end	Revenue (\$m)	PBT (\$m)	EPSA* (c)	DPS (c)	P/E (x)	Yield (%)
12/15	4,634	1,040	85.1	30.8	20.6	1.8
12/16	4,669	965	82.6	30.8	21.2	1.8
12/17e	4,790	939	87.6	32.3	20.0	1.8
12/18e	5,015	1,017	94.0	35.5	18.7	2.0

Source: Smith & Nephew, Bloomberg. Note: \*Before amortisation of intangibles.

**Price** **1,360p**
**Market cap** **£12bn**

\$1.29/E

### Share price graph



### Share details

Code	SN
Listing	LSE
Shares in issue	875m

### Business description

Smith & Nephew is a leading UK-based maker of medical devices. It is the world's number one in arthroscopy products; two in advanced wound management; three in trauma and extremities products; and number four in orthopaedic reconstruction products.

### Bull

- Strength in attractive market niches, such as arthroscopy, endoscopy and wound care.
- Recent acquisitions have been strategically sensible, alongside divestment of its gynaecology business, from which shareholders are benefiting via a share buyback.
- The biggest European medical device maker, which the specialist and popular press have mentioned as an M&A target.

### Bear

- Growth continues to be modulated by FX, a larger manufacturing base than competitors and economic conditions in various markets.
- Consolidation of hospital buying patterns plays in favour of even bigger medical device companies.
- Product pricing is likely to stay challenging, as healthcare funding remains under pressure.

### Analysts

Dr Andy Smith	+44 (0)20 3077 5738
Dr Dan Wilkinson	+44 (0)20 3077 5734

[healthcare@edisongroup.com](mailto:healthcare@edisongroup.com)

**Smith & Nephew is a client of  
Edison Investment Research  
Limited**

Edison, the investment intelligence firm, is the future of investor interaction with corporates. Our team of over 100 analysts and investment professionals work with leading companies, fund managers and investment banks worldwide to support their capital markets activity. We provide services to more than 400 retained corporate and investor clients from our offices in London, New York, Frankfurt and Sydney. Edison is authorised and regulated by the [Financial Conduct Authority](#). Edison Investment Research (NZ) Limited (Edison NZ) is the New Zealand subsidiary of Edison. Edison NZ is registered on the New Zealand Financial Service Providers Register (FSP number 247505) and is registered to provide wholesale and/or generic financial adviser services only. Edison Investment Research Inc (Edison US) is the US subsidiary of Edison and is regulated by the Securities and Exchange Commission. Edison Investment Research Limited (Edison Aus) [46085869] is the Australian subsidiary of Edison and is not regulated by the Australian Securities and Investment Commission. Edison Germany is a branch entity of Edison Investment Research Limited [4794244]. [www.edisongroup.com](http://www.edisongroup.com)

#### DISCLAIMER

Copyright 2017 Edison Investment Research Limited. All rights reserved. This report has been commissioned by Smith & Nephew and prepared and issued by Edison for publication globally. All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report. Opinions contained in this report represent those of the research department of Edison at the time of publication. The securities described in the Investment Research may not be eligible for sale in all jurisdictions or to certain categories of investors. This research is issued in Australia by Edison Aus and any access to it, is intended only for "wholesale clients" within the meaning of the Australian Corporations Act. The Investment Research is distributed in the United States by Edison US to major US institutional investors only. Edison US is registered as an investment adviser with the Securities and Exchange Commission. Edison US relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. As such, Edison does not offer or provide personalised advice. We publish information about companies in which we believe our readers may be interested and this information reflects our sincere opinions. The information that we provide or that is derived from our website is not intended to be, and should not be construed in any manner whatsoever as, personalised advice. Also, our website and the information provided by us should not be construed by any subscriber or prospective subscriber as Edison's solicitation to effect, or attempt to effect, any transaction in a security. The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are "wholesale clients" for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. This document is provided for information purposes only and should not be construed as an offer or solicitation for investment in any securities mentioned or in the topic of this document. A marketing communication under FCA rules, this document has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research. Edison has a restrictive policy relating to personal dealing. Edison Group does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Edison may have a position in any or related securities mentioned in this report. Edison or its affiliates may perform services or solicit business from any of the companies mentioned in this report. The value of securities mentioned in this report can fall as well as rise and are subject to large and sudden swings. In addition it may be difficult or not possible to buy, sell or obtain accurate information about the value of securities mentioned in this report. Past performance is not necessarily a guide to future performance. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a "personalised service" and, to the extent that it contains any financial advice, is intended only as a "class service" provided by Edison within the meaning of the FAA (ie without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision. To the maximum extent permitted by law, Edison, its affiliates and contractors, and their respective directors, officers and employees will not be liable for any loss or damage arising as a result of reliance being placed on any of the information contained in this report and do not guarantee the returns on investments in the products discussed in this publication. FTSE International Limited ("FTSE") (c) FTSE [2017]. "FTSE()" is a trade mark of the London Stock Exchange Group companies and is used by FTSE International Limited under license. All rights in the FTSE indices and/or FTSE ratings vest in FTSE and/or its licensors. Neither FTSE nor its licensors accept any liability for any errors or omissions in the FTSE indices and/or FTSE ratings or underlying data. No further distribution of FTSE Data is permitted without FTSE's express written consent.